




Investor Overview

March 2026

*Trusted Solutions,
Improving Lives™*



Cautionary Note Regarding Forward-Looking Statements

Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures

This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements include statements with respect to targeted EPS growth, targeted dividend rates, future acquisition behavior and investment plans, targeted gross leverage ratio, targeted free cash flow conversion and near-term capital allocation plans. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this presentation. The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries; the impact of severe weather events, natural disasters and public health threats; economic and political consequences resulting from terrorist attacks, wars and global conflicts; IDEX’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; cybersecurity incidents; the continued growth of artificial intelligence (“AI”) and any related changes in AI-driven markets served by IDEX’s customers; the relationship of the U.S. Dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in countries in which IDEX operates; developments with respect to trade policy and existing, new or increased tariffs or other similar measures; changes to applicable laws and regulations, including tax laws; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in IDEX’s most recent annual report on Form 10-K filed with the United States Securities and Exchange Commission. The forward-looking statements included here are only made as of the date of this presentation, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

Non-GAAP Measures. This presentation includes certain non-GAAP financial measures, including adjusted net income, adjusted EBITDA, adjusted EBITDA margin, adjusted earnings per share (EPS), free cash flow and free cash flow conversion. Reconciliations of non-GAAP measures are included on slides 23-26 of this presentation.



About IDEX

IDEX at a Glance

Global engineered products company focused on delivering mission critical solutions, pivoting towards higher growth, specialized markets

- Well-positioned with proprietary, specialized technologies across a diverse set of markets
- IDEX 8020 operating model supports growth and world-class execution
- Established culture of agility and autonomy across businesses positions us to serve as trusted partners to our customers and support their needs with speed
- Global brands supporting customers in over 100 countries

HST: Health & Science Technologies FMT: Fluid & Metering Technologies
FSDP: Fire & Safety / Diversified Products



~8,700
EMPLOYEES

\$3.5B
2025 REVENUE

\$926M
2025 ADJ.
EBITDA**

\$617M
2025 FCF**



* Percentages illustrate the share of 2025 net sales contributed by each segment on the basis of total segments.

** These are non-GAAP measures. See reconciliations to the most directly comparable GAAP measures on slides 23-26.

IDEX Value Drivers

Differentiated **8020** operating model drives full business potential through simplification, focused resourcing and streamlined execution

Focused on continuously **evolving our portfolio** toward high-growth, advantaged markets with secular tailwinds

Disciplined capital allocation with **strong deployable cash flow** that supports M&A, dividends and share repurchases

Focused on delivering **above-market organic growth and margins, amplified by strategic M&A** to drive sustainable value creation

Targeting compounding double-digit EPS growth long-term

8020 Culture Drives Sustainable Growth and Value Creation

Operational Excellence

- ✓ Solving critical engineering needs
- ✓ Removing complexity to drive efficient operations
- ✓ Empowering our teams to serve customers with speed and agility

Enterprise Growth

- ✓ Segmenting and prioritizing high-value customers
- ✓ Focusing sales, service and innovation efforts on perceived highest yield prospects
- ✓ Self-funding growth initiatives

Portfolio Optimization, Capital Allocation

- ✓ Pivoting business and product portfolio towards higher growth and value creation
- ✓ Enhancing platforms by reducing complexity and exposures to low value-add areas
- ✓ Maintaining a balanced, returns-focused capital allocation philosophy

The Purposeful Evolution of IDEX

Staging sustainable value creation in Phase III

\$3.5B
2025
REVENUES

PHASE III

PATH TO HIGHER GROWTH WITH 8020

- 1) *Targeting higher-growth, advantaged markets*
- 2) *Accelerating commercial and operational business integration*
- 3) *Balanced, returns-focused capital deployment*

PHASE II

OPTIMIZED WITH 8020

Introduced **8020**, accelerated talent development, applied shared operating approach and enhanced margins across the portfolio

PHASE I

HOLDING COMPANY, EST 1987

Portfolio of resilient industrial products with strong brands operating independently

2011 2012

2020 2021



Trusted Solutions,
Improving Lives™

1) Targeting Higher-Growth, Advantaged Markets

8020 Focus: Enhance portfolio through proprietary M&A and selective divesture

EXAMPLES OF TARGETED, ADVANTAGED MARKETS

Data Centers



Recent acquisitions


Airtech and Muon

Space and Defense



Iridian, STC, Muon, Mott, Micro-Lam

Semiconductor



Muon and Mott

Water



Nexsight and Subterra

IDEX capabilities

Thermal management

Communication and guidance

Wafer manufacturing

Analytical insights

2) Commercial & Operational Business Integration


8020 Focus: Integrate technologies and market access points within growth platforms

Materials Science Solutions Platform



Offering all three is a competitive advantage

FUNCTION
Enable surface function:
optical, electrical, chemical



MATERIALS
Form critical properties

Operational integration
streamlines costs,
improves productivity

SHAPE
Create & control physical
nature of surfaces

Integrated platform capabilities enable IDEX to deliver differentiated value

3) Balanced Capital Deployment

8020 Focus: Near-term, target bolt-on acquisitions and returning capital to shareholders

Framework for Returns-Focused Capital Allocation

M&A	Dividends	Share Repurchase
<ul style="list-style-type: none">▪ Core to our growth compounding strategy▪ Scaling critical capabilities in advantaged markets▪ Continuous portfolio optimization	<ul style="list-style-type: none">▪ Delivering reliable and consistent dividends▪ Target of 30-35% of adj. net income	<ul style="list-style-type: none">▪ Increased repurchase authorization to \$1 billion (Sept '25)

Current focus: balancing return of capital to shareholders with growth investment

Building High Margin Growth Platforms in Advantaged Markets

MEGATRENDS

AI & Digitization | Regionalization & Defensive Industrialization | Reimagined Supply Chains
Energy Efficiency | Demographic Shifts

Health & Science Technologies

Materials Science Solutions

Leading-edge portfolio of applied materials forming capabilities focused on rapidly growing, nascent markets

Life Sciences

Unique innovative solutions built on broad toolkit for global pharma and life science customers

Fluid & Metering Technologies

Severe Duty Flow Control

Differentiated rugged technologies ensuring high reliability and uptime in high-risk applications

Intelligent Water

Wastewater monitoring and analytics mitigating infrastructure risk and ensuring efficient investment

Fire & Safety / Diversified Products

Fire & Safety

On-scene automation and tools delivering mission-critical tech in “life & death” situations

Implementing 8020 Across Platforms

Reallocating Resources

Leveraging Adjacent Technologies

Maximizing Go-to-market Synergies

Delivering Operational Efficiencies

IDEX Business Overview

IDEX Business Characteristics

Business Model

- ✓ Manufacturing focus on components, subcomponents and modules
- ✓ High criticality but small portion of customers' bill of materials
- ✓ Asset-light manufacturing and efficient operations
- ✓ Proprietary, customer co-developed, and differentiated technology

Competitive Advantage

- ✓ Industry leaders
- ✓ High margins with room to grow
- ✓ Favorable end market secular trends
- ✓ Long-tenured customer relationships and collaboration with emerging innovators
- ✓ Proprietary technology that can be tuned for new opportunities in adjacent spaces



We choose specialized spaces where we can optimize growth and profitability, turning proprietary technology into new opportunities


Segments Summary

Health & Science Technologies

\$1.5B
2025 Sales

~43%
of 2025 Segment Sales

26.6%
2025 Adj. EBITDA%




Fluid & Metering Technologies

\$1.2B
2025 Sales

~35%
of 2025 Segment Sales

33.2%
2025 Adj. EBITDA %




Fire & Safety / Diversified Products

\$0.75B
2025 Sales

~22%
of 2025 Segment Sales

28.7%
2025 Adj. EBITDA %



Percent of sales

Organizational Strengths

8020 | Innovation | Disciplined Strategic Acquisitions | Emerging Markets



Trusted Solutions,
Improving Lives™


* These are non-GAAP measures. See reconciliations to their most directly comparable U.S. GAAP financial measures on slides 23-26

Segment Snapshot: Health & Science Technologies

Reporting Units

Reporting Unit	2025 Sales
Scientific Fluidics & Optics	57%
Performance Pneumatics Technologies	17%
Sealing Solutions	17%
Material Processing Technologies	9%


Financial Performance (\$M)



Key End Markets

- Life Sciences
- Space & Defense
- Semiconductor
- Food & Beverage
- Energy

Segment Revenue



- ✓ Technology driven optics, fluidics, filtration and pneumatics for precise handling of light, gas and liquids
- ✓ Direct co-development with market leading OEMs
- ✓ Integrated platforms drive technology roadmap and cross-business unit customer relationships
- ✓ Focus area of organic and inorganic growth investment

Segment Snapshot: Fluid & Metering Technologies

Reporting Units


Reporting Unit	2025 Sales
Pumps	35%
Water	29%
Energy	17%
Agriculture	11%
Valves	8%

2025 Sales


Key End Markets

- Industrial
- Water
- Energy
- Chemical
- Agriculture

Segment Revenue



Financial Performance (\$M)



- ✓ Highly engineered pumps and valves solving customer challenges for durability in severe conditions
- ✓ Established, premium flow control brands sold via leading distribution channels
- ✓ Investing in digitization for sales, fulfillment and maintenance
- ✓ Local-for-local in emerging regions driving growth in India, Middle East and Southeast Asia

Segment Snapshot: Fire & Safety / Diversified Products


Reporting Units

Fire and Safety
Dispensing
BAND-IT

2025 Sales

64%
20%
16%


Financial Performance (\$M)



Key End Markets

- Fire Suppression
- Paint Dispensing
- Aerospace/Defense
- Rescue Tools
- Automotive & Aviation




Segment Revenue



- ✓ Mission-critical products for life saving emergency situations in Fire & Rescue
- ✓ Strength in design and production for growing needs in emerging markets
- ✓ Investing in automation capabilities to meet customer staffing challenges

Financial Performance

Strong Record of Sales and Earnings Growth, Primed for Acceleration




- 2019 – 2022 → high-single-digit revenue and adjusted EPS CAGRs driven by pandemic and rebound demand
- Coming out of pandemic, life sciences and semiconductor markets contracted, pressuring recent growth and EPS expansion – we expect EPS growth in 2026
- Capital deployed in high-value markets tied to secular mega trends and enhancing scale to drive acceleration towards sustainable double-digit EPS growth




* These are non-GAAP measures. See reconciliations to their most directly comparable U.S. GAAP financial measures on slides 23-26.

Healthy Balance Sheet and Strong Cash Generation Support Financial and Strategic Flexibility

Gross Leverage Ratio



Free Cash Flow & Conversion Rate* (\$M)



- Target <2.0x leverage with capacity for M&A
- Track record of quickly deleveraging after deals

- Deployment of strong FCF compounds returns
- Targeting 100%+ FCF conversion

IDEX Value Drivers

Differentiated **8020** operating model drives full business potential through simplification, focused resourcing and streamlined execution

Focused on continuously **evolving our portfolio** toward high-growth, advantaged markets with secular tailwinds

Balanced allocator of capital with **strong deployable cash flow** that supports M&A, dividends and share repurchases

Focused on delivering **above-market organic growth and margins, amplified by strategic M&A** to drive sustainable value creation

Targeting compounding double-digit EPS growth long-term

Non-GAAP Reconciliations

Reconciliations of Net Income to Adjusted EBITDA

(dollars in millions)

	For the Years Ended December 31,						
	2019	2020	2021	2022	2023	2024	2025
Reported net income	\$ 425.5	\$ 377.8	\$ 449.3	\$ 586.7	\$ 595.6	\$ 504.6	\$ 482.5
Provision for income taxes	107.4	92.5	130.5	162.7	164.7	134.7	150.1
Interest expense - net	44.3	44.8	41.0	40.7	51.7	44.5	64.4
Gain on sale of businesses	-	-	-	(34.8)	(84.7)	(4.0)	-
Depreciation	39.6	41.7	46.6	50.7	57.2	68.5	75.8
Amortization	37.4	41.8	56.4	69.0	94.9	107.1	130.7
Fair value inventory step-up charges	3.3	4.1	11.6	8.5	1.6	9.6	0.6
Restructuring expenses and asset impairments	21.0	11.8	9.3	4.5	10.9	9.3	20.7
Loss on early debt redemption	-	8.4	8.6	-	-	-	-
Termination of the U.S. pension plan, net of curtailment	-	-	8.6	-	-	-	-
Corporate transaction indemnity	-	-	3.5	-	-	-	-
(Gain) loss on sales of assets	-	-	-	(2.7)	-	-	1.1
Net impact from the exit of a COVID-19 testing application ⁽¹⁾	-	-	-	(1.1)	-	-	-
Credit loss on note receivable from collaborative partner ⁽²⁾	-	-	-	-	7.7	-	-
Adjusted EBITDA	\$ 678.5	\$ 622.9	\$ 765.4	\$ 884.2	\$ 899.6	\$ 874.3	\$ 925.9
Net sales	\$ 2,494.6	\$ 2,351.6	\$ 2,764.8	\$ 3,181.9	\$ 3,273.9	\$ 3,268.8	\$ 3,457.5
Impact from the exit of a COVID-19 testing application ⁽¹⁾				(17.9)			
Adjusted net sales				\$ 3,164.0			
Net income margin	17.1%	16.1%	16.3%	18.4%	18.2%	15.4%	14.0%
Adjusted EBITDA margin	27.2%	26.5%	27.7%	27.9%	27.5%	26.7%	26.8%

⁽¹⁾ The impact to Net sales and Gross margin represents the acceleration of previously deferred revenue of \$17.9 million as a result of a customer's decision to discontinue further investment in commercializing its COVID-19 testing application, which was largely offset by an impairment charge of \$16.8 million, resulting in a \$1.1 million impact on net income.

⁽²⁾ Represents a reserve on an investment with a collaborative partner recorded in Other (income) expense – net during the second quarter of 2023. During the fourth quarter of 2023, the Company converted the promissory note receivable from the collaborative partner to equity, resulting in a cost method investment with zero value.

Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX

(in millions)

	For the Years Ended December 31,						
	2019	2020	2021	2022	2023	2024	2025
Reported net income attributable to IDEX	\$ 425.5	\$ 377.8	\$ 449.4	\$ 586.9	\$ 596.1	\$ 505.0	\$ 483.2
Fair value inventory step-up charges	3.3	4.1	11.6	8.5	1.6	9.6	0.6
Tax impact on fair value inventory step-up charges	(0.7)	(0.9)	(2.7)	(2.2)	(0.4)	(2.0)	(0.1)
Restructuring expenses and asset impairments	21.0	11.8	9.3	4.5	10.9	9.3	20.4
Tax impact on restructuring expenses and asset impairments	(4.9)	(2.8)	(2.2)	(0.9)	(2.5)	(2.2)	(5.1)
Net impact from the exit of a COVID-19 testing application ⁽¹⁾	-	-	-	(1.1)	-	-	-
Tax impact on the exit of a COVID-19 testing application	-	-	-	0.3	-	-	-
Loss on early debt redemption	-	8.4	8.6	-	-	-	-
Tax impact on loss on early debt redemption	-	(1.9)	(1.8)	-	-	-	-
Termination of the U.S. pension plan, net of curtailment	-	-	8.6	-	-	-	-
Tax impact on termination of the U.S. pension plan, net of curtailment	-	-	(1.9)	-	-	-	-
Corporate transaction indemnity	-	-	3.5	-	-	-	-
Tax impact on corporate transaction indemnity	-	-	(0.8)	-	-	-	-
Gain on sale of businesses	-	-	-	(34.8)	(84.7)	(4.0)	-
Tax impact on gain on sale of businesses	-	-	-	5.5	22.7	-	-
(Gain) loss on sales of assets	-	-	-	(2.7)	-	-	1.1
Tax impact on (gain) loss on sales of assets ⁽²⁾	-	-	-	0.6	-	-	0.5
Credit loss on note receivable from collaborative partner ⁽³⁾	-	-	-	-	7.7	-	-
Tax impact on credit loss on note receivable from collaborative partner	-	-	-	-	(1.6)	-	-
Acquisition-related intangible asset amortization	37.3	41.8	56.4	69.0	94.9	107.1	130.7
Tax impact on acquisition-related intangible asset amortization	(8.5)	(9.6)	(12.9)	(15.5)	(21.1)	(24.3)	(31.8)
Adjusted net income attributable to IDEX	\$ 473.0	\$ 428.7	\$ 525.1	\$ 618.1	\$ 623.6	\$ 598.5	\$ 599.5

⁽¹⁾ Represents the net impact of the acceleration of previously deferred revenue of \$17.9 million and an impairment charge of \$16.8 million as a result of a customer's decision to discontinue further investment in commercializing its COVID-19 testing application.

⁽²⁾ In 2025, the loss on sale of assets generated tax expense due to the characterization of the underlying assets sold for tax purposes.

⁽³⁾ Represents a reserve on an investment with a collaborative partner recorded in Other (income) expense – net during the second quarter of 2023. During the fourth quarter of 2023, the Company converted the promissory note receivable from the collaborative partner to equity, resulting in a cost method investment with zero value.

Reconciliations of Diluted EPS Attributable to IDEX

(in millions, except per share amounts)

	For the Years Ended December 31,						
	2019	2020	2021	2022	2023	2024	2025
Reported diluted EPS attributable to IDEX	\$ 5.56	\$ 4.94	\$ 5.88	\$ 7.71	\$ 7.85	\$ 6.64	\$ 6.41
Fair value inventory step-up charges	0.04	0.05	0.15	0.11	0.02	0.13	0.01
Tax impact on fair value inventory step-up charges	(0.01)	(0.01)	(0.04)	(0.03)	-	(0.02)	-
Restructuring expenses and asset impairments	0.28	0.15	0.12	0.06	0.15	0.12	0.27
Tax impact on restructuring expenses and asset impairments	(0.07)	(0.03)	(0.03)	(0.01)	(0.03)	(0.03)	(0.07)
Net impact from the exit of a COVID-19 testing application ⁽¹⁾	-	-	-	(0.01)	-	-	-
Tax impact on the exit of a COVID-19 testing application	-	-	-	-	-	-	-
Loss on early debt redemption	-	0.11	0.11	-	-	-	-
Tax impact on loss on early debt redemption	-	(0.02)	(0.02)	-	-	-	-
Termination of the U.S. pension plan, net of curtailment	-	-	0.11	-	-	-	-
Tax impact on termination of the U.S. pension plan, net of curtailment	-	-	(0.02)	-	-	-	-
Corporate transaction indemnity	-	-	0.05	-	-	-	-
Tax impact on corporate transaction indemnity	-	-	(0.01)	-	-	-	-
Gain on sale of businesses	-	-	-	(0.46)	(1.12)	(0.05)	-
Tax impact on gain on sale of businesses	-	-	-	0.07	0.30	-	-
(Gain) loss on sales of assets	-	-	-	(0.03)	-	-	0.02
Tax impact on (gain) loss on sales of assets ⁽²⁾	-	-	-	0.01	-	-	0.01
Credit loss on note receivable from collaborative partner ⁽³⁾	-	-	-	-	0.10	-	-
Tax impact on credit loss on note receivable from collaborative partner	-	-	-	-	(0.02)	-	-
Acquisition-related intangible asset amortization	0.49	0.55	0.74	0.91	1.25	1.41	1.72
Tax impact on acquisition-related intangible asset amortization	(0.11)	(0.13)	(0.17)	(0.21)	(0.28)	(0.31)	(0.42)
Adjusted diluted EPS attributable to IDEX	\$ 6.18	\$ 5.61	\$ 6.87	\$ 8.12	\$ 8.22	\$ 7.89	\$ 7.95
Diluted weighted average shares outstanding	76.5	76.4	76.4	76.0	75.9	75.9	75.3



⁽¹⁾ Represents the net impact of the acceleration of previously deferred revenue of \$17.9 million and an impairment charge of \$16.8 million as a result of a customer's decision to discontinue further investment in commercializing its COVID-19 testing application.

⁽²⁾ In 2025, the loss on sale of assets generated tax expense due to the characterization of the underlying assets sold for tax purposes.

⁽³⁾ Represents a reserve on an investment with a collaborative partner recorded in Other (income) expense – net during the second quarter of 2023. During the fourth quarter of 2023, the Company converted the promissory note receivable from the collaborative partner to equity, resulting in a cost method investment with zero value.

Reconciliations of Cash Flows from Operating Activities to Free Cash Flow

(dollars in millions)

	For the Years Ended December 31,						
	2019	2020	2021	2022	2023	2024	2025
Cash flows from operating activities	\$ 528.1	\$ 569.3	\$ 565.3	\$ 557.4	\$ 716.7	\$ 668.1	\$ 680.4
Less: Capital expenditures	50.9	51.6	72.7	68.0	89.9	65.1	63.6
Free cash flow	\$ 477.2	\$ 517.7	\$ 492.6	\$ 489.4	\$ 626.8	\$ 603.0	\$ 616.8
Reported net income attributable to IDEX	\$ 425.5	\$ 377.8	\$ 449.4	\$ 586.9	\$ 596.1	\$ 505.0	\$ 483.2
Adjusted net income attributable to IDEX	444.2	396.5	525.1	618.1	623.6	598.5	599.5
Operating cash flow as a percent of net income	124%	151%	126%	95%	120%	132%	141%
Free cash flow conversion	107%	131%	94%	79%	101%	101%	103%